Non-Necroptotic Roles of MLKL in Diet-Induced Obesity, Liver Pathology, and Insulin Sensitivity: Insights from a High-Fat, High-Fructose, High-Cholesterol Diet Mouse Model
Authors:
- Phoebe Ohene-MarfoPhoebe Ohene-Marfo
- Hoang Van M. NguyenHNHoang Van M. Nguyen
- Sabira MohammedSMSabira Mohammed
- Nidheesh ThadathilNTNidheesh Thadathil
- Albert TranATAlbert Tran
- Evan H. NicklasENEvan H. Nicklas
- Dawei WangDWDawei Wang
- Ramasamy SelvaraniRSRamasamy Selvarani
- Jacob W. FarriesterJFJacob W. Farriester
- Rohan VarshneyRVRohan Varshney
- Michael KinterMKMichael Kinter
- Arlan RichardsonARArlan Richardson
Open Access
- 28 February 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (5) , 2813
Abstract
Chronic inflammation is a key player in metabolic dysfunction-associated fatty liver disease (MAFLD) progression. Necroptosis, an inflammatory cell death pathway, is elevated in MAFLD patients and mouse models, yet its role is unclear due to the diverse mouse models and inhibition strategies. In our study, we inhibited necroptosis by targeting mixed lineage kinase domain-like pseudokinase (MLKL), the terminal effector of necroptosis, in a high-fat, high-fructose, high-cholesterol (HFHFrHC) mouse model of diet-induced MAFLD. Despite the HFHFrHC diet upregulating MLKL (2.5-fold), WT mice livers showed no increase in necroptosis markers or associated proinflammatory cytokines. Surprisingly, Mlkl−/− mice experienced exacerbated liver inflammation without protection from diet-induced liver damage, steatosis, or fibrosis. In contrast, Mlkl+/− mice showed a significant reduction in these parameters that was associated with elevated Pparα and Pparγ levels. Both Mlkl−/− and Mlkl+/− mice on the HFHFrHC diet resisted diet-induced obesity, attributed to the increased beiging, enhanced oxygen consumption, and energy expenditure due to adipose tissue, and exhibited improved insulin sensitivity. These findings highlight the tissue-specific effects of MLKL on the liver and adipose tissue, and they suggest a dose-dependent effect of MLKL on liver pathology.Keywords
All Related Versions
Funding Information
- NIH (R01AG059718, R03 CA262044, HF21-009, 5R24GM137786, 5P30AG050911, 5P20GM103447)
- Oklahoma Center for Adult Stem Cell Research Grant (OCASCR) (R01AG059718, R03 CA262044, HF21-009, 5R24GM137786, 5P30AG050911, 5P20GM103447)
- Oklahoma Center for the Advancement of Science and Technology (OCAST) (R01AG059718, R03 CA262044, HF21-009, 5R24GM137786, 5P30AG050911, 5P20GM103447)
- Presbyterian Health Foundation (R01AG059718, R03 CA262044, HF21-009, 5R24GM137786, 5P30AG050911, 5P20GM103447)
This publication has 69 references indexed in Scilit:
- Macrophage‐derived MLKL in alcohol‐associated liver disease: Regulation of phagocytosisHepatology, 2023
- The necroptosis-inducing pseudokinase mixed lineage kinase domain-like regulates the adipogenic differentiation of pre-adipocytesiScience, 2022
- Role of necroptosis in chronic hepatic inflammation and fibrosis in a mouse model of increased oxidative stressFree Radical Biology and Medicine, 2021
- The potential role of necroptosis in inflammaging and agingGeroScience, 2019
- Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant CandidatesClinical Gastroenterology and Hepatology, 2019
- MLKL, the Protein that Mediates Necroptosis, Also Regulates Endosomal Trafficking and Extracellular Vesicle GenerationImmunity, 2017
- PPARs and nonalcoholic fatty liver diseaseBiochimie, 2017
- Receptor interacting protein 3 protects mice from high‐fat diet‐induced liver injuryHepatology, 2016
- Necroptosis in Nonalcoholic SteatohepatitisCellular and Molecular Gastroenterology and Hepatology, 2015
- The Pseudokinase MLKL Mediates Necroptosis via a Molecular Switch MechanismImmunity, 2013